论文部分内容阅读
目的观察恶性淋巴细胞增殖性疾病患者血清可溶性细胞间粘附分子１（ｓＩＣＡＭ１）水平的变化及其与病情、疗效的关系。方法采用亲合素和生物素标记的酶联免疫法，对多发性骨髓瘤（ＭＭ）、恶性淋巴瘤（ＭＬ）及急性淋巴细胞白血病（ＡＬＬ）患者化疗前后血清ｓＩＣＡＭ１水平进行检测。结果２２例ＭＭ患者中９例（４１％）、３２例非霍奇金淋巴瘤（ＮＨＬ）患者中１７例（５３％）、１９例ＡＬＬ患者中１２例（６３％）的血清ｓＩＣＡＭ１水平高于正常。血清ｓＩＣＡＭ１水平，ＭＭ患者中受Ｃ反应蛋白和β２微球蛋白为依据的Ｂａｔａｉｌｅ分期的影响，与Ｄｕｒｉｅ分期无关；ＮＨＬ患者中，与病理类型、ＡｎｎＡｒｂｏｒ分期、Ｂ症状有关，与血清乳酸脱氢酶无关；ＡＬＬ患者中，合并中枢神经系统白血病者明显高于未合并者。血清ｓＩＣＡＭ１升高者与血清ｓＩＣＡＭ１正常者比较，前者疗效较差。动态观察发现，随着病情缓解，血清ｓＩＣＡＭ１水平亦降至正常。结论血清ｓＩＣＡＭ１水平的检测有助于判断患者的病情及疗效。
Objective To observe the changes of serum soluble intercellular adhesion molecule-1 (sICAM-1) levels in patients with malignant lymphocyte proliferative disorders and its relationship with disease status and efficacy. Methods The levels of serum sICAM-1 in patients with multiple myeloma (MM), malignant lymphoma (ML) and acute lymphoblastic leukemia (ALL) before and after chemotherapy were measured by avidin and biotin-labeled enzyme-linked immunosorbent assay. Results Serum sICAM-1 levels were found in 9 (41%) of 22 MM patients, in 17 (53%) of 32 non-Hodgkin’s lymphoma (NHL) patients and in 12 (63%) of 19 ALL patients. Above normal. Serum sICAM-1 level, Bataile staging based on C-reactive protein and β2 microglobulin in MM patients was not associated with Durie stage, and was associated with pathological type, Ann Arbor stage, B symptoms, and serum lactate in NHL patients. Hydrogenase has nothing to do; in patients with ALL, patients with central nervous system leukemia were significantly higher than those who did not. The serum sICAM-1 increased compared with the normal serum sICAM-1, the former less effective. Dynamic observation found that serum sICAM-1 levels also decreased to normal levels as the disease eased. Conclusion The detection of serum sICAM-1 level can help determine the condition and efficacy of patients.